Understanding the TXA seizure connection

Debra A. Schwinn, G. Burkhard Mackensen, and Emery N. Brown

1Department of Anesthesiology, Pharmacology, and Biochemistry, Roy J. and Lucille A. Carver College of Medicine, The University of Iowa, Iowa City, Iowa, USA. 2Department of Anesthesiology and Pain Medicine, University of Washington, Seattle, Washington, USA. 3Department of Brain and Cognitive Sciences, MIT-Harvard Division of Health Science and Technology, Massachusetts Institute of Technology, Cambridge, Massachusetts, USA.

Tranexamic acid (TXA) is an antifibrinolytic that has been used successfully to prevent blood loss during major surgery. However, as its usage has increased, there have been growing reports of postsurgical seizure events in cardiac surgery patients. In this issue of the *JCI*, Lecker et al. explore this connection and suggest that TXA-mediated inhibition of glycine receptors may underlie the effect. This finding prompted the authors to explore the preclinical efficacy of common anesthetics that function by reducing the TXA-mediated inhibition to prevent or modify postsurgical seizures.

Introduction


Tranexamic acid (TXA) is an antifibrinolytic that has been used successfully to prevent blood loss during major surgery. However, as its usage has increased, there have been growing reports of postsurgical seizure events in cardiac surgery patients. In this issue of the *JCI*, Lecker et al. explore this connection and suggest that TXA-mediated inhibition of glycine receptors may underlie the effect. This finding prompted the authors to explore the preclinical efficacy of common anesthetics that function by reducing the TXA-mediated inhibition to prevent or modify postsurgical seizures.

Introduction


Tranexamic acid (TXA) is an antifibrinolytic that has been used successfully to prevent blood loss during major surgery. However, as its usage has increased, there have been growing reports of postsurgical seizure events in cardiac surgery patients. In this issue of the *JCI*, Lecker et al. explore this connection and suggest that TXA-mediated inhibition of glycine receptors may underlie the effect. This finding prompted the authors to explore the preclinical efficacy of common anesthetics that function by reducing the TXA-mediated inhibition to prevent or modify postsurgical seizures.

Introduction


Tranexamic acid (TXA) is an antifibrinolytic that has been used successfully to prevent blood loss during major surgery. However, as its usage has increased, there have been growing reports of postsurgical seizure events in cardiac surgery patients. In this issue of the *JCI*, Lecker et al. explore this connection and suggest that TXA-mediated inhibition of glycine receptors may underlie the effect. This finding prompted the authors to explore the preclinical efficacy of common anesthetics that function by reducing the TXA-mediated inhibition to prevent or modify postsurgical seizures.
are less well defined. In contrast, for propofol, which is known to act by enhancing GABAA receptor inhibition, systems neuroscience analyses now provide highly plausible neural circuit details of how its actions at GABAA receptors in the cortex, thalamus, and brainstem can lead to unconsciousness and sedation (15).

Seizures, typically characterized as hypersynchronous neuronal activity due to unbalanced, uncontrolled excitation, arise through multiple mechanisms (16), and establishing the precise cause is often a challenge. Conditions such as fevers, infection, and brain trauma that enhance neural activity can make seizures more likely. One possible mechanism is loss of control in key GABAergic inhibitory circuits (16). The findings in the current study suggest that inactivation of glycine-mediated circuits, which are also inhibitory networks, may be an alternative mechanism for seizure induction. Although propofol and inhaled anesthetics are not first-line therapies for seizures, they are the last-line therapy for status epilepticus, as they place the patient in a drug-induced coma (17). This coma is typically induced and maintained by sustained delivery of sufficient doses of the anesthetic until the seizure activity, monitored by EEG, converts to a desired level of burst suppression. The presumed mechanisms of action are enhanced GABAergic inhibition (18), as well as metabolically induced opening of ATP-dependent potassium channels (19). The seizure activity is arrested, but the mechanism of the therapy may not relate to the mechanism of the seizure. Therefore, it is highly plausible, as suggested by Lecker and colleagues, that propofol or isoflurane could be used to treat seizures associated with TXA, especially since their in vitro findings suggest that these drugs can directly block glycine-mediated activation induced by TXA.

Unanswered questions
Since TXA binds competitively to GABA type A receptors, it is perhaps no surprise that an association between TXA and postoperative seizures is found (20). However, it is unclear why most episodes of seizures occur during the immediate postoperative hours, a time when levels of intraperitoneally administered TXA in the serum and cerebrum should already be declining. One possibility is that TXA induces modifications (neuroplasticity) in these inhibitory circuits that outlast its pharmacological time course. In addition, TXA is known to cross the blood-brain barrier (BBB), especially when BBB integrity is challenged. Thus, the higher incidence of TXA-related seizures in patients undergoing open-heart procedures may relate to disruption of BBB integrity by cerebral emboli, which are known to be much more prevalent during open-heart procedures versus coronary artery bypass grafting (21). This may also explain why Lecker et al. found higher-than-expected TXA concentrations in CSF from a patient undergoing major aortic surgery, where BBB disruption is also common. Lecker et al. also demonstrated that TXA binds to glycine receptors, at least in mice (1). Thus, competitive antagonism of both glycine and GABA receptors may serve as one plausible explanation for the association between TXA and postoperative seizures (20).

The next fundamental question is whether TXA-induced convulsions are true seizures or, as some researchers and caregivers report, dystonic movements more akin to those seen in strychnine poisoning. This latter possibility is intriguing given that strychnine is also a competitive glycine receptor antagonist (22). Unfortunately EMG and EEG recordings of the events are lacking due to unexpected timing of these incidents, and it is unknown whether patients have residual cognitive defects. Historically, patients who have seizures after cardiac surgery generally have higher incidence of postoperative neurologic complications, defined as stroke and delirium (8), but it is unclear whether these complications also follow TXA-induced seizures, which are generally easily treated.

Lecker et al. examined possible mechanisms to prevent TXA-induced seizures. Their study elegantly demonstrates that TXA inhibition of glycine receptors activated by a low concentration of glycine is reversed by isoflurane at clinically relevant concentrations, as well as to a lesser extent by propofol (1). Most patients receive sedation (such as continuous propofol infusion) until they are extubated postoperatively in the ICU, a process that may initially mask (or prevent) the occurrence of seizures.

Summary
In the article in this issue of the JCI, Lecker et al. provide new information on the mechanism underlying TXA-induced seizures, specifically elucidation of competitive inhibition by TXA of CNS-derived inhibitory glycine receptors. They also demonstrate that TXA inhibition of glycine receptors activated by a low concentration of glycine is reversed by isoflurane at clinically relevant concentrations, as well as to a lesser extent by propofol. These findings suggest that risk for TXA-induced seizures may be reduced by modifying (decreasing) TXA exposure by using a lower-dose regimen, or that seizures may be prevented with the use of isoflurane or propofol after surgery. Since early extubation and shorter ICU time after major surgery correlate with better patient outcome, it may not be practical to continue an anesthetized state for very long after surgery. However, anesthetics have multiple targets, and since most of their transmitted effects are inhibitory, it is likely that various combinations of drugs may work to provide the desired anticonvulsant effects. The use of agents that prevent glycine inhibition by TXA, as reported by the authors, certainly is one intriguing possibility.

Acknowledgments
The authors are funded by grants from NIH to D.A. Schwinn (HL49103) and E.N. Brown (DP1OD003646).

Address correspondence to: Debra A. Schwinn, Dean, Roy J. and Lucille A. Carver College of Medicine, Professor of Anesthesiology, Pharmacology and Biochemistry, The University of Iowa, 212 CMAB, 451 Newton Road, Iowa City, Iowa 52242-1101, USA. Phone: 319.384.4547; Fax: 319.353.5617; E-mail: debra-schwinn@uiowa.edu.


6. Hurton B, Joseph L, Fergusson D, Mazzer CD, Shapiro S, Timmough A. Risks of harms using antifibrinolytics in cardiac surgery: systematic review and network meta-analysis of randomised and observa-
7. Bohacs PM, et al. A phase 2 prospective, randomised, double-blind trial comparing the effects of tranexamic acid with ecallantide on blood loss from high-risk cardiac surgery with cardiopulmo-
Are epins a therapeutic target for tumor angiogenesis?

Nancy Klauber-DeMore

Department of Surgery, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA.

Solid tumor growth requires the formation of new blood vessels to supply nutrients and oxygen to the malignant cells; one approach to cancer therapy is to block this process by inhibiting VEGF signaling. In this issue of the JCI, Pasula et al. demonstrate a surprising role of epins — proteins involved in endocytosis — in tumor angiogenesis via their modulation of VEGF signaling. Their findings suggest that these proteins might represent a new target for the development of cancer therapeutics.

Angiogenesis is the formation of new capillary blood vessels and is a critical component of solid tumor growth (1). Once a new tumor reaches just a few cubic millimeters in size, further growth must be preceded by angiogenesis. Tumor cells secrete soluble factors that stimulate vessel growth and/or suppress factors that prevent angiogenesis. These factors act upon endothelial cells to promote their proliferation and migration, resulting in sprouting and tube formation; those tubes then develop into vessels.

Although tumor angiogenesis can be understood as a process required to sustain a cancer’s blood supply, the vascular network induced as a result of tumor angiogenesis is highly aberrant, altering the tumor microenvironment and profoundly influencing the manner in which cancers grow, escape the host’s immune system, and metastasize (2). Unlike the organized microvasculature of normal tissue, tumor microvessels are dilated and tortuous, with disorganized patterns of interconnection and branching (3). The erratic tumor vasculature and the resultant hypoxia have additional consequences for tumors: cancer cells undergo epigenetic changes in hypoxic conditions that accelerate their malignant phenotype and the epithelial-to-mesenchymal transition, producing a greater metastatic potential (2). In addition, the cytotoxic functions of immune cells that infiltrate a tumor are compromised in hypoxic and low pH conditions, further contributing to the malignant phenotype (4).

**VEGF family**

An essential mediator of angiogenesis is the VEGF family, which consists of five family members of secreted proteins (VEGFA, VEGFB, VEGFC, VEGFD, VEGFE, and PDGF) (5), that bind and activate three receptor tyrosine kinases (VEGFR1, -2, and -3) (6) which in turn mediate cell signaling. VEGFR2 is the key mediator of VEGF-stimulated tumor angiogenesis. When VEGF ligands VEGFR2, the receptor is phosphorylated and activates downstream signaling molecules, resulting in endothelial cell proliferation, migration, tube formation, and the induction of antiapoptotic gene expression (7). VEGF signaling also causes tortuous vascular formation and vascular leakage in tumors.

**Inhibiting VEGF is a therapeutic strategy to inhibit tumor growth**

With the discovery of VEGF as a major driver of tumor angiogenesis, efforts have focused on the development of therapeutics to inhibit VEGF activity, with the goal of inducing tumor regression by starvation. In 2004, a humanized monoclonal antibody to VEGFA, bevacizumab (Avastin; Genentech), became the first FDA-approved antiangiogenic drug in the United States (8). It was approved as a first-line treatment agent for metastatic colorectal cancer, in combination with 5-fluorouracil (9), and was subsequently approved for treatment of metastatic non–squamous-cell lung cancer, breast cancer, and glioblastoma multiforme (10). FDA approval was withdrawn for metastatic breast cancer because follow-up studies failed to show an improvement in overall survival. Additional FDA-approved drugs that block VEGF...